Trial · NCT02681913
Adenosine as an Adjunct to Blood Cardioplegia
NCT02681913, Phase 2, Unknown, Amphia Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adenosine as an Adjunct to Blood Cardioplegia. Trials, record NCT02681913. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02681913
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adenosine as an Adjunct to Blood Cardioplegia
- NCT number
- NCT02681913
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Amphia Hospital
- Conditions
- Pathological Processes, Cardiomyopathies
- Interventions
- Adenosine
- First posted
- 2016-02-15
- Last updated
- 2017-04-20
- Other registries' IDs
- eudract:2015-001923-22
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 6-hour cardiac Troponin T (cTnT) release | 6 hours post-operative | The primary end point is 6-hour cTnT release |
| Secondary | 18-hour cardiac Troponin T (cTnT) area under the curve (AUC) release | cardiac Troponin T (cTnT) AUC will be assessed at different time points, the latest up to 18 hours after ICU arrival | 18-hour postoperative AUC release of cardiac troponin T Routine blood samples pre-operatively from peripheral blood (T0); post-operatively, from peripheral blood, at arrival at ICU (T1) and 6 hours after arrival at ICU (T2), and 18 hours after arrival at ICU (T3). |
| Secondary | Incidence of myocardial injury on 12-lead ECG | participants will be followed for the duration of ICU stay, an expected average of 2 days | Incidence of myocardial injury on 12-lead ECG * New-onset Left bundle branch block (LBBB) * New-onset Q wave |
| Secondary | Vasoactive-inotropic score | participants will be followed for the duration of ICU stay, an expected average of 2 days | The hourly doses of the following inotropic and vasoactive medications are recorded for the first 18 h after post-operative admission to the ICU: dopamine, dobutamine, epinephrine, norepinephrine, milrinone and vasopressin. |
| Secondary | Vasoconstrictor usage | participants will be followed for the duration of ICU stay, an expected average of 2 days | Vasoconstrictor usage yes/no |
| Secondary | Incidence of new onset Atrial fibrillation (AF) | participants will be followed for the duration of ICU stay, an expected average of 2 days | Incidence of new onset AF |
| Secondary | Routine blood samples | Routine blood samples will be assessed at different time points, the latest up to 6 hours after ICU arrival | The amount of creatine kinase MB (CK-MB) and Creatinine at different time intervals. preoperatively from peripheral blood (T0); post-operatively, from peripheral blood, at arrival at ICU (T1) and 6 hours after arrival at ICU (T2) |
| Secondary | Mean arterial pressure (MAP) | participants will be followed for the duration of ICU stay, an expected average of 2 days | Haemodynamic monitoring |
| Secondary | postoperative left ventricular ejection fraction (LVEF) | postoperative after skin closure, an expected average of 3 hours after starting surgery | 3-D transesophageal echocardiography (TEE) postoperative left ventricular ejection fraction (LVEF) after skin closure |
| Secondary | Wall Motion Score Index (WMSI) | postoperative after skin closure, an expected average of 3 hours after starting surgery | 3-D transesophageal echocardiography (TEE) Wall Motion Score Index (WMSI) after skin closure |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02681913
GET https://conductscience.org/api/trials/v1/NCT02681913/registered